

Effects of Ramipril on Coronary Events in High-Risk Pe

Circulation

104, 522-526

DOI: [10.1161/hc3001.093502](https://doi.org/10.1161/hc3001.093502)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Expression of CYR61, an Angiogenic Immediate Early Gene, in Arteriosclerosis and Its Regulation by Angiotensin II. <i>Circulation</i> , 2002, 106, 254-260.	1.6	103
2	Î±-Tocopherol protects against diet induced atherosclerosis in New Zealand white rabbits. <i>Journal of Lipid Research</i> , 2002, 43, 1927-1938.	2.0	30
3	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2002, 23, 1809-1840.	1.0	764
4	Current World Literature. <i>Current Opinion in Anaesthesiology</i> , 2002, 15, 263-282.	0.9	0
5	Ramipril reduces the risk of myocardial infarction, angina and coronary revascularization for high-risk patients. <i>Evidence-based Cardiovascular Medicine</i> , 2002, 6, 26-27.	0.0	0
6	Ramipril. <i>Drugs</i> , 2002, 62, 1381-1405.	4.9	56
7	Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. <i>Lancet, The</i> , 2002, 359, 926-930.	6.3	297
9	Chronic Renal Ischemia: Implications for Cardiovascular Disease Risk. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, 1187-1198.	0.2	15
10	Kinins, the long march--A personal view. <i>Cardiovascular Research</i> , 2002, 54, 485-491.	1.8	36
11	Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002, 90, 1045-1049.	0.7	27
12	Vascular inflammation as a therapeutic target for prevention of cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2002, 4, 77-81.	2.0	8
14	Angiotensin inhibition and coronary autoregulation in a canine model of LV hypertrophy. <i>Basic Research in Cardiology</i> , 2002, 97, 384-391.	2.5	19
15	Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 1967-1971.	1.0	6
16	Stressing the system. <i>European Journal of Clinical Investigation</i> , 2003, 33, 635-641.	1.7	3
17	Direct biochemical evidence for eNOS stimulation by bradykinin in the human forearm vasculature. <i>Basic Research in Cardiology</i> , 2003, 98, 84-89.	2.5	22
18	Coronary heart disease: the female heart is vulnerable. <i>Progress in Cardiovascular Diseases</i> , 2003, 46, 199-229.	1.6	115
19	Prevention and management of chronic heart failure in patients at risk. <i>American Journal of Cardiology</i> , 2003, 91, 10-17.	0.7	20
20	The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. <i>American Journal of Cardiology</i> , 2003, 91, 28-34.	0.7	52

#	ARTICLE	IF	CITATIONS
22	Renal Ischemia as a Predictor of Cardiovascular Morbidity. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, P159-P164.	0.2	0
23	ACE INHIBITORS AND SURVIVAL IN DIALYSIS PATIENTS: EFFECTS ON SERUM POTASSIUM?. <i>American Journal of Kidney Diseases</i> , 2003, 41, 520-521.	2.1	4
24	Angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers: what we know and current controversies. <i>Critical Care Nursing Clinics of North America</i> , 2003, 15, 423-437.	0.4	0
25	ACE INHIBITORS AND SURVIVAL IN DIALYSIS PATIENTS: EFFECTS ON SERUM POTASSIUM? In Reply. <i>American Journal of Kidney Diseases</i> , 2003, 41, 521.	2.1	1
26	A review of anti-inflammatory strategies in cardiac surgery. <i>Perfusion (United Kingdom)</i> , 2003, 18, 7-12.	0.5	28
27	Exercise and the Nitric Oxide Vasodilator System. <i>Sports Medicine</i> , 2003, 33, 1013-1035.	3.1	268
28	Determinants of Quality of In-Hospital Care for Patients with Acute Coronary Syndromes. <i>Disease Management and Health Outcomes</i> , 2003, 11, 801-816.	0.3	1
29	Drug Therapy and Heart Failure Prevention. <i>Circulation</i> , 2003, 107, 1234-1236.	1.6	18
30	Prevention of Cardiovascular Ischemic Events. <i>Circulation</i> , 2003, 107, 2059-2065.	1.6	47
31	Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 62-73.	1.0	9
32	Drug Therapy for Prevention of Recurrent Myocardial Infarction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1465-1477.	0.9	21
33	How should we implement current evidence on ACE-inhibition in the treatment of patients surviving a myocardial infarction?. <i>Scandinavian Cardiovascular Journal</i> , 2003, 37, 122-123.	0.4	0
34	Effect of Chronic Treatment with Vitamin E on Endothelial Dysfunction in a Type I in Vivo Diabetes Mellitus Model and in Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 114-122.	1.3	30
35	Drug induced QT prolongation and torsades de pointes. <i>British Heart Journal</i> , 2003, 89, 1363-1372.	2.2	796
36	PPOGRESS beyond HOPE and LIFE: The ONTARGET trial programme. <i>European Heart Journal Supplements</i> , 2003, 5, F40-F47.	0.0	1
37	Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril. <i>European Heart Journal Supplements</i> , 2003, 5, A31-A36.	0.0	11
38	New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. <i>Journal of Hypertension</i> , 2003, 21, 1599-1608.	0.3	33
39	Short-term Effects of Exogenous Angiotensin II on Plasma Fibrinolytic Balance in Normal Subjects. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 13-26.	0.5	13

#	ARTICLE	IF	CITATIONS
40	Endocardial endothelium in the avascular frog heart: role for diffusion of NO in control of cardiac O2 consumption. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H14-H21.	1.5	13
41	Long-term outcomes of optimized medical management of outpatients with stable coronary artery disease. American Journal of Cardiology, 2004, 93, 294-299.	0.7	27
44	Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events. Pharmacoeconomics, 2004, 22, 955-973.	1.7	20
45	Impaired Glucose Metabolism in Patients with Heart Failure. American Journal of Cardiovascular Drugs, 2004, 4, 269-280.	1.0	32
47	Differences in Clinical Profile and Outcome in Patients With Decompensated Heart Failure and Systolic Dysfunction or Preserved Systolic Function. Revista Espanola De Cardiologia (English Ed), 2004, 57, 45-51.	0.4	11
48	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 68-70.	0.0	0
49	Ischemic heart disease in women and the role of hormone therapy. International Journal of Cardiology, 2004, 96, 7-19.	0.8	17
50	Prevalence of unrecognized abnormal glucose tolerance in patients attending a hospital hypertension clinic. American Journal of Hypertension, 2004, 17, 483-488.	1.0	13
51	Hypertension and the Elderly: More Than Just Blood Pressure Control. Journal of Clinical Hypertension, 2004, 6, 249-255.	1.0	15
54	Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clinical Therapeutics, 2004, 26, 460-472.	1.1	17
55	What does the lipoprotein oxidation phenomenon mean?. Biochemical Society Transactions, 2004, 32, 160-163.	1.6	6
56	Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2005, 294, 1794.	3.8	66
57	Stability of ramipril in the solvents of different pH. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 1179-1183.	1.4	18
59	Hipertensi3n arterial y riesgo cardiovascular en el a2004. Revista Espanola De Cardiologia Suplementos, 2005, 5, 24A-34A.	0.2	2
60	Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell and Tissue Research, 2005, 320, 437-445.	1.5	108
61	Metabolic syndrome and endothelial dysfunction. Current Hypertension Reports, 2005, 7, 88-95.	1.5	79
63	Angiotensin II and Aldosterone Regulate Gene Transcription Via Functional Mineralocorticoid Receptors in Human Coronary Artery Smooth Muscle Cells. Circulation Research, 2005, 96, 643-650.	2.0	313
64	Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?. Heart, 2005, 91, 1-2.	1.2	163

#	ARTICLE	IF	CITATIONS
65	The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. <i>European Heart Journal</i> , 2005, 26, 1369-1378.	1.0	127
66	The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2005, 65, 143-156.	0.6	55
67	Hypertension as a hemodynamic disease: The role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. <i>American Journal of Hypertension</i> , 2005, 18, 26-43.	1.0	70
69	How Does Renal Intervention Compare to Medical Management Alone?. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, P100-P103.	0.2	0
71	Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1576-1583.	1.2	145
72	Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: Rationale and design of the CORAL trial. <i>American Heart Journal</i> , 2006, 152, 59-66.	1.2	271
73	New Definitions of Hypertension. <i>Journal of Clinical Hypertension</i> , 2006, 8, 282-283.	1.0	1
74	Gender differences across racial and ethnic groups in the quality of care for acute myocardial infarction and heart failure associated with comorbidities. <i>Women's Health Issues</i> , 2006, 16, 44-55.	0.9	62
75	Stable Angina. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, S4-S9.	2.2	2
76	Treatments for the Metabolic Syndrome. , 2006, , 381-406.		1
77	Cardiac event rate in a lifestyle modification program for patients with chronic coronary artery disease. <i>Clinical Cardiology</i> , 2006, 29, 317-321.	0.7	4
78	Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 98, 758-760.	0.7	10
79	Differential diagnosis of elevated troponins. <i>Heart</i> , 2006, 92, 987-993.	1.2	286
80	Clinical Decision-Making in Blood Pressure Management of Patients with Diabetes Mellitus: An Oklahoma Physicians Resource/Research Network (OKPRN) Study. <i>Journal of the American Board of Family Medicine</i> , 2006, 19, 232-239.	0.8	16
81	The Diabetic Kidney. , 2006, , .		1
82	Modified Low-Density Lipoproteins and High-Density Lipoproteins. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 322-345.	0.5	8
83	Effect of drug combinations on admission for recurrent myocardial infarction. <i>Heart</i> , 2007, 93, 1226-1230.	1.2	18
84	Treatment of stable angina. <i>Heart</i> , 2007, 93, 868-874.	1.2	11

#	ARTICLE	IF	CITATIONS
85	Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis. <i>Heart</i> , 2007, 93, 848-855.	1.2	83
86	Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. <i>Heart</i> , 2007, 93, 914-921.	1.2	108
88	Cardiovascular magnetic resonance in the evaluation of heart failure. <i>Heart</i> , 2007, 93, 985-992.	1.2	33
89	Is Renal Artery Stenting the Correct Treatment of Renal Artery Stenosis?. <i>Circulation</i> , 2007, 115, 263-270.	1.6	41
90	Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications. <i>Current Nutrition and Food Science</i> , 2007, 3, 194-199.	0.3	4
91	Improving end-of-life care for patients with chronic heart failure: "Let's hope it'll get better, when I know in my heart of hearts it won't". <i>Heart</i> , 2007, 93, 963-967.	1.2	153
92	MANAGEMENT OF END STAGE HEART FAILURE. <i>Heart</i> , 2007, 93, 626-631.	1.2	74
94	Pigment Epithelium-Derived Factor (PEDF) Inhibits Angiotensin III-induced Smooth Muscle Cell Proliferation Through Its Anti-Oxidative Properties. <i>Protein and Peptide Letters</i> , 2007, 14, 615-617.	0.4	10
95	Defining the Role of Zofenopril in the Management of Hypertension and Ischemic Heart Disorders. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 17-24.	1.0	42
97	Nitric Oxide and Cardiovascular Risk Factors. <i>Heart International</i> , 2007, 3, 182618680700300.	0.4	8
98	Myocardial infarction: contemporary management strategies. <i>Journal of Internal Medicine</i> , 2007, 262, 59-77.	2.7	15
99	Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the "prior event rate ratio"™ to adjust for unmeasured confounding by indication. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 671-685.	0.9	36
100	Implicaciones clínicas del programa ONTARGET en pacientes con cardiopatía isquémica crónica. <i>Revista Española De Cardiología Suplementos</i> , 2008, 8, 63E-72E.	0.2	1
101	Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An International Verapamil SR-Trandolapril (INVEST) substudy. <i>American Heart Journal</i> , 2008, 156, 241-247.	1.2	48
102	Determining the most appropriate components for a composite clinical trial outcome. <i>American Heart Journal</i> , 2008, 156, 633-640.	1.2	38
103	The role of percutaneous revascularization for renal artery stenosis. <i>Vascular Medicine</i> , 2008, 13, 141-156.	0.8	38
104	Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge. <i>Vascular Disease Prevention</i> , 2008, 5, 246-251.	0.2	0
105	Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes. Focus on Rampiril. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2095.	0.1	0

#	ARTICLE	IF	CITATIONS
106	The Impact of Diabetes Mellitus on Coronary Artery Disease: New Therapeutic Approaches. <i>Current Pharmaceutical Design</i> , 2009, 15, 2037-2048.	0.9	14
107	Eligibility of Individuals With Subclinical Coronary Artery Calcium and Intermediate Coronary Heart Disease Risk for Reclassification (from the Framingham Heart Study). <i>American Journal of Cardiology</i> , 2009, 103, 1710-1715.	0.7	27
108	Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 161-170.	1.3	27
109	Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 641-648.	1.0	13
110	Diabetes and Cardiovascular Disease Prevention in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 607-641.	1.0	44
112	Renin-angiotensin system blockade in older adults with chronic kidney disease: a review of the literature. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 413-419.	1.0	9
113	ACE INHIBITOR POSSIBILITIES IN CLINICAL PRACTICE: WHAT WE KNOW ABOUT THEM?. <i>Rational Pharmacotherapy in Cardiology</i> , 2010, 6, 528-531.	0.3	0
115	Congestive heart failure and use of ACE inhibitors in the horse. <i>Equine Veterinary Education</i> , 2002, 14, 304-306.	0.3	0
116	Simultaneous Quantitative Determination of Metoprolol, Atorvastatin and Ramipril in Capsules by a Validated Stability-Indicating RP-UPLC Method. <i>Scientia Pharmaceutica</i> , 2010, 78, 821-834.	0.7	21
117	Nitrite and Nitrate in Human Health and Disease. , 2011, , .		45
118	Pathophysiology of Atherosclerosis: The Role of Inflammation. <i>Current Pharmaceutical Design</i> , 2011, 17, 4089-4110.	0.9	96
120	Novel Pharmacological Interventions to Maintain Sinus Rhythm after DC Cardioversion. <i>ISRN Cardiology</i> , 2011, 2011, 1-7.	1.6	0
121	Aldosterone Regulates Vascular Gene Transcription via Oxidative Stress-Dependent and -Independent Pathways. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1871-1880.	1.1	78
122	Cardiac Myocyte-Fibroblast Interactions and the Coronary Vasculature. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 783-793.	1.1	17
124	Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives. <i>Current Vascular Pharmacology</i> , 2012, 10, 19-32.	0.8	88
126	Mineralocorticoid receptors in vascular function and disease. <i>Molecular and Cellular Endocrinology</i> , 2012, 350, 256-265.	1.6	142
127	Cost-effectiveness of enzyme replacement therapy for Fabry disease. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 29.	1.2	58
128	Mineralocorticoid Receptors in Vascular Disease: Connecting Molecular Pathways to Clinical Implications. <i>Current Atherosclerosis Reports</i> , 2013, 15, 340.	2.0	23

#	ARTICLE	IF	CITATIONS
129	Development and validation of an rp-hplc method for simultaneous determination of Ramipril and Amlodipine in tablets. <i>Journal of Pharmaceutical Analysis</i> , 2013, 3, 440-446.	2.4	11
130	Aldosterone Increases Early Atherosclerosis and Promotes Plaque Inflammation Through a Placental Growth Factor-Dependent Mechanism. <i>Journal of the American Heart Association</i> , 2013, 2, e000018.	1.6	102
131	Antioxidants in Health and Disease. , 2013, , 319-339.		0
132	Aldosterone and Vascular Mineralocorticoid Receptors. <i>Hypertension</i> , 2014, 63, 632-637.	1.3	33
133	Minimizing Systemic Inflammation During Cardiopulmonary Bypass in the Pediatric Population. <i>Artificial Organs</i> , 2014, 38, 11-18.	1.0	53
134	Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease. <i>Steroids</i> , 2014, 91, 38-45.	0.8	72
135	Five-Year Prognosis After Endovascular Therapy in Claudicant Patients With Iliofemoral Artery Disease. <i>Journal of Endovascular Therapy</i> , 2014, 21, 381-388.	0.8	15
136	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806.		2
137	Vascular Complications of Diabetes Mellitus. , 2015, , 1541-1593.		0
139	Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. <i>European Heart Journal</i> , 2015, 36, 3134-3146.	1.0	177
140	From the 1990s to CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) Trial Results and Beyond: Does Stenting Have a Role in Ischemic Nephropathy?. <i>American Journal of Kidney Diseases</i> , 2015, 65, 611-622.	2.1	11
141	Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv346.	0.4	81
142	Drug Treatment of Hypertension: Focus on Vascular Health. <i>Drugs</i> , 2016, 76, 1529-1550.	4.9	53
143	In Reply-“The Different Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality. <i>Mayo Clinic Proceedings</i> , 2016, 91, 972-975.	1.4	1
144	The Importance of Identifying Early Changes in Cardiac Structure and Function for the Prevention of Cognitive Impairment and Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 285-288.	1.2	1
145	Do Renin-Angiotensin Blockers Affect Renal Function and Cardiac Outcomes in Patients Undergoing Partial Nephrectomy?. <i>Journal of Urology</i> , 2017, 197, 566-573.	0.2	5
146	Antioxidants in Health and Disease. , 2017, , 321-346.		9
147	Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome. <i>Pediatric Nephrology</i> , 2018, 33, 1183-1187.	0.9	15

#	ARTICLE	IF	CITATIONS
167	Drug Therapy and Follow-Up. , 2011, , 563-631.		0
168	Nutritional Impact on the Nitric Oxide Pathway. , 2011, , 97-122.		0
169	Recent Trials in Hypertension. , 0, , .		0
170	Vascular Complications of Diabetes Mellitus. , 2014, , 1-65.		0
171	Hypertension in African Americans. , 2015, , 233-249.		0
172	Nutritional Impact on the Nitric Oxide Pathway. , 2017, , 111-128.		0
173	Comparison of clinical outcomes between ACE inhibitor and ARB in AMI patients with dyslipidemia after successful stent implantation. Anatolian Journal of Cardiology, 2019, 23, 86-98.	0.5	6
174	Diabetic Renal and Related Heart Disease. , 2006, , 437-451.		0
175	Lesions and lipids and radicals--O my!. Texas Heart Institute Journal, 2004, 31, 118-26.	0.1	1
176	Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vascular Health and Risk Management, 2005, 1, 183-98.	1.0	468
177	Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. Scripta Medica, 2022, 53, 51-76.	0.0	3
179	Discontinuation of RASi and Clinical Events in Advanced Chronic Kidney Disease: A Prospective Cohort Study in 10,400 Patients with Type 2 Diabetes. SSRN Electronic Journal, 0, , .	0.4	0
180	Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective. Swiss Medical Weekly, 0, , .	0.8	7
181	Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study. EClinicalMedicine, 2023, 55, 101751.	3.2	12